EUVIMEDEUVIMED entdecken
Klinische StudieOpen Access

Three-Year Update of Tisagenlecleucel in Pediatric and Young Adult Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia in the ELIANA Trial

Theodore W Laetsch iD, Shannon L Maude iD, Susana Rives iD, Hidefumi Hiramatsu, Henrique Bittencourt iD, Peter Bader iD, André Baruchel iD, Michael Boyer, Barbara De Moerloose iD, Muna Qayed iD, Jochen Buechner iD, Michael A Pulsipher iD und 14 weitere

Journal of Clinical Oncology · 20.03.2023 · 41 (9) · 1664-1669

DOI: 10.1200/jco.22.00642 ↗

Kurz gefasst

Klinische Studie in der Zeitschrift Journal of Clinical Oncology, erschienen am 20.03.2023. Verfasst von Theodore W Laetsch und 25 weiteren Autor:innen. Beteiligte Einrichtung: Division of Oncology, Center for Childhood Cancer Research and Cancer Immunotherapy Program, Children's Hospital of Philadelphia, Philadelphia, PA. Hauptthemen laut MEDLINE: Precursor Cell Lymphoblastic Leukemia-Lymphoma, Quality of Life. Die Arbeit wurde bisher 389-mal zitiert (Crossref) und nennt 9 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Clinical trials frequently include multiple end points that mature at different times. The initial report, typically based on the primary end point, may be published when key planned co-primary or secondary analyses are not yet available. Clinical Trial Updates provide an opportunity to disseminate additional results from studies, published in JCO or elsewhere, for which the primary end point has already been reported. In the primary analysis of the global phase II ELIANA trial (ClinicalTrials.gov identifier: NCT02435849 ), tisagenlecleucel provided an overall remission rate of 81% in pediatric and young adult patients with relapsed or refractory B-cell acute lymphoblastic leukemia (R/R B-ALL), with 59% of responders remaining relapse-free at 12 months. Here, we report an update on efficacy, safety, and patient-reported quality of life in 79 pediatric and young adult patients with R/R B-ALL following a median follow-up of 38.8 months. The overall remission rate was 82%. The median event-free survival was 24 months, and the median overall survival was not reached. Event-free survival was 44% (95% CI, 31 to 57) and overall survival was 63% (95% CI, 51 to 73) at 3 years overall (most events occur within the first 2 years). The estimated 3-year relapse-free survival with and without censoring for subsequent therapy was 52% (95% CI, 37 to 66) and 48% (95% CI, 34 to 60), respectively. No new or unexpected long-term adverse events were reported. Grade 3/4 adverse events were reported in 29% of patients > 1 year after infusion; grade 3/4 infection rate did not increase > 1 year after infusion. Patients reported improvements in quality of life up to 36 months after infusion. These findings demonstrate favorable long-term safety and suggest tisagenlecleucel as a curative treatment option for heavily pretreated pediatric and young adult patients with R/R B-ALL.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Precursor Cell Lymphoblastic Leukemia-LymphomaQuality of LifeChildHumansYoung AdultChronic DiseaseReceptors, Antigen, T-CellRecurrence

Substanzen

Receptors, Antigen, T-Celltisagenlecleucel

Autor:innen und Institutionen

  • Division of Oncology, Center for Childhood Cancer Research and Cancer Immunotherapy Program, Children's Hospital of Philadelphia, Philadelphia, PA.
  • Department of Pediatrics, Abramson Cancer Center, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA.
  • Department of Pediatric Hematology-Oncology and Institut de Recerca, Hospital Sant Joan de Déu Barcelona, Barcelona, Spain.
  • Department of Pediatrics, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
  • Department of Pediatrics, Faculty of Medicine, University of Montreal, Montreal, Canada.
  • The Hematology Oncology Division and Charles-Bruneau Cancer Center, Centre Hospitalier Universitaire Sainte-Justine, Montreal, Canada.

ORCID-Profile: Theodore W Laetsch, Shannon L Maude, Susana Rives, Henrique Bittencourt, Peter Bader, André Baruchel, Barbara De Moerloose, Muna Qayed, Jochen Buechner, Michael A Pulsipher, Christina Peters, Seong Lin Khaw, Kara L Davis, Adriana Balduzzi, Stephan A Grupp

Zitieren

APA

Laetsch, T. W., Maude, S. L., Rives, S., Hiramatsu, H., Bittencourt, H., Bader, P., Baruchel, A., Boyer, M., De Moerloose, B., Qayed, M., Buechner, J., Pulsipher, M. A., Myers, G. D., Stefanski, H. E., Martin, P. L., Nemecek, E., Peters, C., Yanik, G., Khaw, S. L., …, & Grupp, S. A. (2023). Three-Year Update of Tisagenlecleucel in Pediatric and Young Adult Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia in the ELIANA Trial. Journal of Clinical Oncology, 41(9), 1664-1669. https://doi.org/10.1200/jco.22.00642

Vancouver

Laetsch TW, Maude SL, Rives S, Hiramatsu H, Bittencourt H, Bader P, et al. Three-Year Update of Tisagenlecleucel in Pediatric and Young Adult Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia in the ELIANA Trial. Journal of Clinical Oncology. 2023;41(9):1664-1669. doi:10.1200/jco.22.00642

BibTeX
@article{Laetsch2023,
  author = {Laetsch, Theodore W and Maude, Shannon L and Rives, Susana and Hiramatsu, Hidefumi and Bittencourt, Henrique and Bader, Peter and Baruchel, André and Boyer, Michael and De Moerloose, Barbara and Qayed, Muna and Buechner, Jochen and Pulsipher, Michael A and Myers, Gary Douglas and Stefanski, Heather E and Martin, Paul L and Nemecek, Eneida and Peters, Christina and Yanik, Gregory and Khaw, Seong Lin and Davis, Kara L and Krueger, Joerg and Balduzzi, Adriana and Boissel, Nicolas and Tiwari, Ranjan and O'Donovan, Darragh and Grupp, Stephan A},
  title = {Three-Year Update of Tisagenlecleucel in Pediatric and Young Adult Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia in the ELIANA Trial},
  journal = {Journal of Clinical Oncology},
  year = {2023},
  volume = {41},
  number = {9},
  pages = {1664--1669},
  doi = {10.1200/jco.22.00642}
}
Kostenlos starten →